Erythropoiesis-stimulating agent

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
星期一, 六月 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Retrieved on: 
星期四, 五月 25, 2023
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, ESA, TD, Erythropoiesis-stimulating agent, NDA, ASCO, MDS, Imetelstat, Corporation, American Society of Clinical Oncology, Geron Corporation, Risk, Syndrome, Randomness, Annual general meeting, Society, Safety, Pharmaceutical industry, Patient

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced acceptance of its IMerge Phase 3 abstract as an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced acceptance of its IMerge Phase 3 abstract as an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • This abstract describes statistically significant positive efficacy and safety data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS).
  • As reported in January 2023, the primary endpoint of 8-week transfusion independence (TI) was met with high statistical significance (P
  • Also, VAF reduction and its correlation to clinical endpoints support imetelstat’s disease-modifying potential, and safety results were consistent with prior reported experience.

Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial

Retrieved on: 
星期三, 四月 26, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, FDA, Health, Other Science, ESA, TD, Erythropoiesis-stimulating agent, ASCO, MDS, Corporation, American Society of Clinical Oncology, Geron Corporation, Syndrome, Risk, Randomness, Annual general meeting, Society, Pharmaceutical industry, Patient

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS), was accepted for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS), was accepted for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • The data in the ASCO abstract will be embargoed per ASCO guidelines until May 25, 2023 at 5 p.m. Eastern Time.
  • ASCO is taking place in Chicago, IL from June 2-6, 2023.
  • Details for the oral presentation are as follows:
    Title: IMerge: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Imetelstat in Patients (pts) With Heavily Transfusion Dependent (TD) Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESA).

Geron Reports Presentations at American Society of Hematology Annual Meeting

Retrieved on: 
星期二, 十二月 14, 2021
Research, Hospitals, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, U.S. Securities and Exchange Commission, ESA, Poster, AML, Survival, LSCS, Company, Azacitidine, MOA, MDS, ESAS, LSC, Population, RBC, Private Securities Litigation Reform Act, Nasdaq, Erythropoiesis-stimulating agent, Acute myeloid leukemia, Immortalised cell line, PDX, Lymphatic system, Thrombocytopenia, Risk, Pharmacokinetics, Malignancy, Nominal interest rate, Geron Corporation, Safety, Patient, MF, Microdeletion syndrome, Disease, Security (finance), Telomerase, Imetelstat, JAK, Vii, Fast Track, ASH, PD, Apoptosis, Mouse, Society, Corporation, Vaccine, Pharmaceutical industry, Medicine, Imetelstat, Geron, IMETELSTAT, GERON

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced three poster presentations related to imetelstat, the Companys first in class telomerase inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced three poster presentations related to imetelstat, the Companys first in class telomerase inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting.
  • We believe the unique telomerase inhibition MOA of imetelstat has the potential to transform the standard of care in hematologic malignancies.
  • Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Implications of Expanded Biosimilar Use in the United States' Dermatology, Gastroenterology, Rheumatology, Ophthalmology, Nephrology, and Neurology Markets Highlighted in New Spherix Study

Retrieved on: 
星期三, 十二月 8, 2021
Merck, Dermatology, Infliximab, Epoetin alfa, Rituximab, AbbVie, Dialysis, Ophthalmology, Safety, Marketing of off-label use, Natalizumab, Rheumatology, Biosimilar, Erythropoiesis-stimulating agent, Nephrology, Neurology, Gastroenterology, Ranibizumab, Mylan, Biogen, Janssen, Amgen, FDA, Roche, Boehringer Ingelheim, Generic drug, Fine chemical

These agents tend to be available at a lower cost point than the branded reference biologics, making them attractive alternative treatment options.

Key Points: 
  • These agents tend to be available at a lower cost point than the branded reference biologics, making them attractive alternative treatment options.
  • Spherix Global Insights has expanded their coverage to assess US specialists' current understanding of the biosimilar landscape, their perceptions of biosimilars, as well as their current (where appropriate) and projected uptake of the agents.
  • Finally, Pfizer's Retacrit, a biosimilar of Amgen's Epogen and Janssen's Procrit, has substantially increased in use across nephrology settings, for both dialysis and non-dialysis.
  • All company, brand or product names in this document are trademarks of their respective holders.

Geron Announces Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting

Retrieved on: 
星期四, 十一月 4, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Safety, Corporation, 2021 Essex County Council election, Annual, PD, Disease, MDS, Survival, Abstract (summary), ESAS, Fast Track, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Security (finance), Cytopenia, Lymphatic system, Immortalised cell line, Apoptosis, ASH, LSCS, Risk, Geron Corporation, Azacitidine, LSC, Microdeletion syndrome, Company, Erythropoiesis-stimulating agent, Acute myeloid leukemia, JAK, Proceedings of the Human Factors and Ergonomics Society Annual Meeting, Nasdaq, AML, MF, PDX, Mouse, Liver, Society, Nominal interest rate, Pharmaceutical industry, Vaccine, Imetelstat, Geron, IMETELSTAT, GERON

We look forward to continued work in these areas as we expand the potential applications for imetelstat in hematologic malignancies.

Key Points: 
  • We look forward to continued work in these areas as we expand the potential applications for imetelstat in hematologic malignancies.
  • In accordance with ASH policies, abstracts submitted to the ASH Annual Meeting are embargoed from the time of submission.
  • To be eligible for presentation at the ASH Annual Meeting, any additional data or information to be presented at the Annual Meeting may not be made public before the presentation.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Dosis Expands Kidney Care Platform With Iron Advisor Tool To Personalize Anemia Management

Retrieved on: 
星期四, 八月 19, 2021
Software, Technology, General Health, Health, SAA, Clinic, ESAS, Patient safety, IV, Artificial intelligence, Science, Erythropoiesis-stimulating agent, Iron, Anemia, Drug utilization review, COO, Patient, CEO, SIA, ESA, Aluminium, Medical imaging

Dosis , a market leader in artificial intelligence-powered precision dosing, today announced the expansion of its kidney care platform with the release of its Strategic Iron Advisor (SIA).

Key Points: 
  • Dosis , a market leader in artificial intelligence-powered precision dosing, today announced the expansion of its kidney care platform with the release of its Strategic Iron Advisor (SIA).
  • SIA is a sub-module that works with Dosiss existing anemia tool, Strategic Anemia Advisor (SAA), to personalize anemia management.
  • SAA is widely used nationwide to personalize Erythropoiesis Stimulating Agents (ESA) dosing, and the SIA offering broadens the capabilities of Dosiss personalized dosing platform.
  • SIA issues dosing recommendations for IV iron, which is often dosed in tandem with ESAs to manage chronic anemia.

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1

Retrieved on: 
星期四, 八月 5, 2021
Biotechnology, Pharmaceutical, Health, Iron-deficiency anemia, Growth, United States dollar, Manuscript, ANCA, Board, Annual, Marketing, Scd, Income, Hospital, Kidney, Blood, Earnings before interest, taxes, depreciation and amortization, Erythropoiesis-stimulating agent, Review, European Medicines Agency, EMA, Cer, Food and Drug Administration, The New England Journal of Medicine, Sickle cell disease, Therapy, Group, CKD, Anemia, Population, Iron, Mortality, Advisory Committee, European Heart Journal, Depreciation, Dialysis, Raasi, Vifor Pharma, File, Quality of life, Leadership, Hyperkalemia, Awareness, European Space Agency, Pharma, Heart failure, Prescription Drug User Fee Act, Adoption, Annual general meeting, Maa, Executive Committee, Patient, COVID-19, PBM, CHF, NDA, Director, Overalls, Heart, Pharmaceutical industry, Medical device, Aquaculture

Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.

Key Points: 
  • Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.
  • Ferinject / Injectafer net sales increased 22.4% (up 22.8% at CER) to CHF 320.5 million in H1 2021 from CHF 261.9 million a year earlier.
  • As a result, Vifor Pharma posted net sales of CHF 73.7 million, up 1.4% or 8.5% at CER.
  • Abbas Hussain was appointed Chief Executive Officer of Vifor Pharma, succeeding Stefan Schulze, who has decided to step down for personal reasons.

The Erythropoietin Stimulating Agents Market in Latin America (2019-2027): Data on Epoetin-Alfa, Epoetin-Beta, Epoetin-Theta, Darbepoetin-Alfa, and Other ESAs

Retrieved on: 
星期三, 十一月 27, 2019
Branches of biology, Medicine, Medical specialties, Growth factors, RTT, Cytokines, Erythropoietin, Hematopoiesis, Erythropoiesis-stimulating agent, Erythropoiesis

DUBLIN, Nov. 27, 2019 /PRNewswire/ -- The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 27, 2019 /PRNewswire/ -- The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America erythropoiesis stimulating agents (ESA) market reached USD 319.2 million in 2018 and is expected to reach USD 533.92 million by 2027, by registering a CAGR of 6.03%, across the region.
  • The demand for erythropoiesis stimulating agents is increasing on the back of the rising demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin.
  • Brazil is slated to account for a share of 44.77% and reach USD 239.03 million by 2027 in the erythropoiesis stimulating agents market.